scholarly journals Clinical case of COVID-19 in a patient treated with alemtuzumab

2021 ◽  
pp. 148-152
Author(s):  
E. V. Popova

The need to review the guidelines for the management of patients with multiple sclerosis using multiple sclerosis disease modifying drugs has become acute enough since the beginning of 2020 following the outbreak of the COVID-19 pandemic caused by a novel coronavirus SARS-CoV-2. Immunosuppressive drugs were also specifically addressed, as it is during administration of these drugs that the more severe course of COVID-19 disease was expected. Both the Russian and foreign teams published results of their research works. This article presents a retrospective analysis of the incidence rates of COVID-19 in patients with multiple sclerosis after selective immunosuppressive therapy with alemtuzumab and a clinical case when a patient was infected with coronavirus in the first days following the last infusion of the therapy course without clinical manifestations of the infectious disease. The author discusses the mechanisms underlying such a favourable outcome due to the CD52 lymphocyte depletion leading to the reduction of risks of developing hyperimmune reactions that underlie severe complications of COVID-19, and analyses previously published works of our foreign colleagues on the same theme. The review of the accumulated works and personal experience suggest that it is the CD52 lymphocyte depletion that makes it possible to avoid the cytokine storm and, as a result, the more severe course of COVID-19. Amidst the COVID-19 pandemic, during the prescription of multiple sclerosis disease modifying drugs, it should be borne in mind that patients should have access to all types of modern therapy and that the benefits should outweigh the sum of possible risks.

2017 ◽  
Vol 47 (5) ◽  
pp. 544-552
Author(s):  
O. V. Bykova ◽  
I. A. Nankina ◽  
I. M. Drozdova ◽  
O. V. Kvasova ◽  
T. T. Batysheva ◽  
...  

2009 ◽  
Vol 25 (4) ◽  
pp. 869-877 ◽  
Author(s):  
Howard G. Birnbaum ◽  
Jasmina I. Ivanova ◽  
Seth Samuels ◽  
Matthew Davis ◽  
Pierre Y. Cremieux ◽  
...  

Author(s):  
Maryam Salehbayat ◽  
◽  
Roya Abolfazli ◽  
Niayesh Mohebbi ◽  
Seyed Mehrdad Savar ◽  
...  

Introduction: High frequency of adverse drug reactions (ADRs) challenges multiple sclerosis (MS) treatment. We aimed to assess the nature and frequency of ADRs induced by MS medications in an observational cross-sectional study. Material and Methods: ADRs of all outpatients who had been visiting a neurologist and had been receiving at least one disease-modifying therapy (DMT) for MS during the last three months were investigated. Results: A total number of 484 ADRs were detected in these patients. The preventability rate was 5.9%, and 0.61% of reactions were serious. Discussion: The high frequency of adverse drug reactions in this study shows a strong need for planning a strategy to increase patients' adherence to treatment.


Author(s):  
Bhupendra Chaudhary ◽  
Rashmi Basvantsing Rajput ◽  
Ansh Chaudhary

Multiple sclerosis being a chronic, autoimmune inflammatory disease of central nervous system with its common and uncommon semiology has a predilection for women of child bearing age. The stressful period of pregnancy is further complicated with presence of multiple sclerosis. Overall multiple sclerosis has stabilising effect on pregnancy especially in its second and third trimester but adversely affects the post-partum period with increasing relapse rate. This is related with intense immune response triggered by marked changes in levels of circulating hormones. A better understanding of anti-natal, natal and post-partum effect of multiple sclerosis helps us to decide for institution or continuation of disease modifying drugs which are generally associated with favourable outcome.


Sign in / Sign up

Export Citation Format

Share Document